Minichromosome maintenance 2 (MCM2) immunoreactivity in stage III human gastric carcinoma: Clinicopathological significance

Gastric Cancer

Volumn 11, Issue 1, 2008, Pages 37-46

  Tokuyasu, Naruo ^a   Shomori, Kohei ^a   Nishihara, Keisuke ^a   Kawaguchi, Hiroki ^b   Fujioka, Shinji ^a   Yamaga, Kensaku ^a   Ikeguchi, Masahide ^a   Ito, Hisao ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b National Hospital Organisation Yonago Medical Center   (Japan)

Author keywords

Gastric carcinoma; Ki 67; Minichromosome maintenance protein 2 (MCM2); p53; Prognostic value

Indexed keywords

KI 67 ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN 2; PROTEIN P53;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER INVASION; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTESTINE CARCINOMA; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; STOMACH CARCINOMA;

AGED; CELL CYCLE PROTEINS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GASTRIC MUCOSA; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MODELS, STATISTICAL; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 41549122447     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-008-0451-1     Document Type: Article

References (39)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827-841.
2. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
3. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-4997.
4. Dimitrova DS, Prokhorova TA, Blow JJ, Todorov IT, Gilbert DM. Mammalian nuclei become licensed for DNA replication during late telophase. J Cell Sci 2002;115:51-59.
5. Blow JJ, Hodgson B. Replication licensing-defining the proliferative state? Trends Cell Biol 2002;12:72-78.
6. Mendez J, Stillman B. Chromatin association of human origin recognition complex, cdc6, and minichromosome maintenance proteins during the cell cycle: assembly of prereplication complexes in late mitosis. Mol Cell Biol 2000;20:8602-8612.
7. Takeda DY, Dutta A. DNA replication and progression through S phase. Oncogene 2005;24:2827-2843.
8. Eward KL, Obermann EC, Shreeram S, Loddo M, Fanshawe T, Williams C, et al. DNA replication licensing in somatic and germ cells. J Cell Sci 2004;117:5875-5886.
9. Stoeber K, Tlsty T, Happerfield L, Thomas G, Romanov S, Bobrow L. DNA replication licensing and human cell proliferation. J Cell Sci 2001;114:2027-2041.
10. Kodani I, Shomori K, Osaki M, Kuratate I, Ryoke K, Ito H: Expression of minichromosome maintenance 2 (MCM2), Ki-67, and cell-cycle-related molecules, and apoptosis in the normaldysplasia-carcinoma sequence of the oral mucosa. Pathobiology 2001;69:150-158.
11. Hashimoto K, Araki K, Osaki M, Nakamura H, Tomita K, Shimizu E, et al. MCM2 and Ki-67 expression in human lung adenocarcinoma: prognostic implications. Pathobiology 2004;71:193-200.
12. Osaki M, Osaki M, Yamashita H, Shomori K, Yoshida H, Ito H. Expression of minichromosome maintenance-2 in human malignant fibrous histiocytomas: correlations with Ki-67 and p53 expression, and apoptosis. Int J Mol Med 2002;10:161-168.
13. Freeman A, Morris LS, Mills AD, Stoeber K, Askey RA, Williams GH, et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 1999;5:2121-2132.
14. Todorov IT, Werness BA, Wang HQ, Buddharaju LN, Todorova PD, Slocum HK, et al. HsMCM2/BM28:a novel proliferation marker for human tumors and normal tissues. Lab Invest 1998;78:73-78.
15. Japanese Gastric Cancer Association Registration Committee. Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer 2006;9:51-66.
16. Lauren P. The two histological main types of gastric cancer: diffuse and so-called intestinal type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49.
17. Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. Tokyo: Kanehara; 1995.
18. Kato H, Miyazaki T, Fukai Y, Nakajima M, Sohda M, Takita J, Masuda N, et al. A new proliferation marker, minichromosome maintenance protein 2, is associated with tumor aggressiveness in esophageal squamous cell carcinoma. J Surg Oncol 2003;84:24-30.
19. Gonzalez MA, Pinder SE, Callagy G, Vowler SL, Morris LS, Bird K, et al. Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J Clin Oncol 2003;21:4306-4313.
20. Hunt DP, Freeman A, Morris LS, Burnet NG, Bird K, Davies TW, et al. Early recurrence of benign meningioma correlates with expression of mini-chromosome maintenance-2 protein. Br J Neurosurg 2002;16:10-15.
21. Wharton SB, Chan KK, Anderson JR, Stoeber K, Williams GH. Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki-67 labelling index, histological grade and prognosis. Neuropathol Appl Neurobiol 2001;27:305-313.
22. Meng MV, Grossfeld GD, Williams GH, Dilworth S, Stoeber K, Mulley TW, et al. Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Clin Cancer Res 2001;7:2712-2718.
23. Rodins K, Cheale M, Coleman N, Fox SB. Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility. Clin Cancer Res 2002;8:1075-1081.
24. Kruger S, Thorns C, Stocker W, Muller-Kunert E, Bohle A, Feller AC. Prognostic value of MCM2 immunoreactivity in stage T1 transitional cell carcinoma of the bladder. Eur Urol 2003;43:138-145.
25. Chatrath P, Scott IS, Morris LS, Davies RJ, Rushbrook SM, Bird K, et al. Aberrant expression of minichromosome maintenance protein-2 and Ki-67 in laryngeal squamous epithelial lesions. Br J Cancer 2003;89:1048-1054.
26. Scholzen T, Gerdes J. The Ki67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-322.
27. Brown DC, Gatter KC. Monoclonal antibody Ki-67:its use in histopathology. Histopathology 1990;17:489-503.
28. Verheijen R, Kuijpers HJ, Schlingemann RO, Boehmer AL, van Driel R, Brakenhoff GJ, et al. Ki-67 detects a nuclear matrix-associated proliferation-related antigen: I. Intracellular localization during interphase. J Cell Sci 1989;92:123-130.
29. Verheijen R, Kuijpers HJ, van Driel R, Beck JL, van Dierendonck JH, Brakenhoff GJ, et al. Ki-67 detects a nuclear matrix-associated proliferation-related antigen. II. Localization in mitotic cells and association with chromosomes. J Cell Sci 1989;92:531-540.
30. Baisch H, Gerdes J. Simultaneous staining of exponentially growing versus plateau phase cells with the proliferation-associated antibody Ki-67 and propidium iodide: analysis by flow cytometry. Cell Tissue Kinet 1987;20:387-391.
31. Müller W, Schneiders A, Meier S, Hommel G, Gabbert HE. Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma. Br J Cancer 1996;74:759-765.
32. Ikeda M, Shomori K, Endo K, Makino T, Matssura T, Ito H. Frequent occurrence of apoptosis is an early event in the oncogenesis of human gastric carcinoma. Virchows Arch 1998;43:43-47.
33. Inada T, Imura J, Ichikawa A, Ogata Y, Shimamura K. Proliferative activity of gastric cancer assessed by immunostaining for proliferating cell nuclear antigen. J Surg Oncol 1993;54:146-152.
34. Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Miwa S, et al. Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J Clin Pathol 2007;60:273-277.
35. Hippo Y, Taniguchi H, Tsusumi S, Machida N, Chong JM, Fukayama M, et al. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 2002;62:233-240.
36. Llanos O, Butte JM, Crovari F, Duarte I, Guzman S. Survival of young patients after gastrectomy for gastric cancer. World J Surg 2006;30:17-20.
37. Kim DY, Joo JK, Ryu SY, Park YK, Kim YJ, Kim SK. Clinocopathologic characteristics of gastric carcinoma in elderly patients: a comparison with young patients. World J Gastroenterol 2005;11:22-26.
38. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2002;13:1977-2000.
39. Ikeguchi M, Saito H, Kondo A, Tsujitani S, Maeta M, Kaibara N. Mutated p53 protein expression and proliferative activity in advanced gastric cancer. Hepatogastroenterology 1999;46:2648-2653.